Please ensure Javascript is enabled for purposes of website accessibility

Vaxart Pushes Ahead With IND Filing for COVID-19 Vaccine Candidate

By Eric Volkman – Aug 10, 2020 at 4:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If approved, the company will soon begin clinical testing of its promising, orally-administered vaccine.

Coronavirus stock Vaxart (VXRT -8.58%) did well on Monday, following the company's latest piece of news regarding its COVID-19 vaccine candidate. The company announced that it filed an Investigational New Drug (IND) application for the candidate.

An IND application is chiefly a request for permission to begin testing a treatment or vaccine on human subjects. Out of an original five it was developing, Vaxart's vaccine candidate is the one the company has chosen for further development. It is unique among current vaccine candidates in that it is the only one that can be taken orally.

A coronavirus colony.

Image source: Getty Images.

Vaxart says this gives it an edge, as oral vaccines are comparatively easier to administer, among other advantages.,et%20al.%2C%202000).

In its press release announcing the IND application, the company said it expects the vaccine candidate to perform very well in clinical testing. It quoted its CEO Andrei Floroiu as saying, "[W]e expect our upcoming Phase I study to generate data that will further differentiate our oral vaccine from injectable vaccines by substantiating the importance of activating both systemic and mucosal immunity in protecting against COVID-19."

Vaxart is one of a fairly large clutch of biotech and pharmaceutical companies around the world working to devise a vaccine. No candidate has yet to complete a full set of clinical trials and win approval for use by a major regulator.

The world remains hopeful for an efficacious vaccine, so Vaxart's news was greeted warmly by investors. The company's stock rose by 2.2% on Monday, well outpacing the gains of the broader equity market.


Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vaxart, Inc. Stock Quote
Vaxart, Inc.
$2.13 (-8.58%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.